ArticleBMC cancer2023

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).

Nan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.